The Satellite Symposium, titled ‘Working towards precision medicine approaches for CLL’, provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), +hb{, Q}ge), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.